ArticleInternational journal of hematology2017

Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.

Kenshi Suzuki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.